BCAX
Bicara Therapeutics Inc.18.15
-0.21-1.14%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
994.29MP/E (TTM)
3.37Basic EPS (TTM)
5.38Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
10-Q
Q2 FY2025 results
Bicara Therapeutics posted a Q2 net loss of $27.4 million, up 61% y/y from $17.0 million, driven by R&D expenses climbing 57% to $24.8 million on clinical trial ramp-up and headcount growth, while G&A rose 85% to $7.2 million amid public company costs. YTD through June 30, 2025, losses widened to $64.2 million from $29.6 million, with R&D surging 112% to $59.1 million fueled by manufacturing and FORTIFI-HN01 Phase 2/3 trial enrollment. Cash burned $53.1 million in H1, leaving $436.6 million at quarter-end, sufficient into mid-2029 per management. No debt; free cash flow not disclosed in the 10-Q. Ongoing Y-Trap patent litigation poses inventorship risks to ficerafusp alfa. Clinical delays could stall pipeline progress.
8-K
Bicara Q2 results and trial updates
Bicara Therapeutics reported Q2 2025 net loss of $27.4 million, up from $17.0 million last year, driven by ramped-up R&D spending on ficerafusp alfa trials. Updated Phase 1/1b data at ASCO 2025 showed 54% ORR and 21.7-month median DOR in HPV-negative HNSCC patients. Cash stands at $436.6 million, funding operations into H1 2029. Additional data expected Q4 2025 to Q1 2026. Clinical progress fuels pivotal trial momentum.
ATRA
Atara Biotherapeutics, Inc.
17.58-0.37
AURA
Aura Biosciences, Inc.
6.18-0.15
BCAB
BioAtla, Inc.
0.76-0.01
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
BCYC
Bicycle Therapeutics plc
7.31-0.02
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CDTX
Cidara Therapeutics, Inc.
220.05-0.05
CNTX
Context Therapeutics Inc.
1.10-0.03
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
TARA
Protara Therapeutics, Inc.
5.42-0.08